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Midazolam Inhibits Hippocampal Long-Term Potentiation
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BenzodiazepineReceptorActivationandNeurosteroidogenesis
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Departments of 1Psychiatry and 2Neurobiology, Washington University School of Medicine, St. Louis, Missouri 63110
Benzodiazepines (BDZs) enhance GABAA receptor inhibition by direct actions on central BDZ receptors (CBRs). Although some BDZs
also bindmitochondrial receptors [translocator protein (18 kDa) (TSPO)] and promote the synthesis of GABA-enhancing neurosteroids,
the role of neurosteroids in the clinical effects of BDZs is unknown. In rat hippocampal slices, we compared midazolam, an anesthetic
BDZ, with clonazepam, an anticonvulsant/anxiolytic BDZ that activates CBRs selectively. Midazolam, but not clonazepam, increased
neurosteroid levels in CA1 pyramidal neurons without changing TSPO immunostaining. Midazolam, but not clonazepam, also aug-
menteda formof spike inhibitionafter stimulationadjacent to thepyramidal cell layer and inhibited inductionof long-termpotentiation.
These effects were prevented by finasteride, an inhibitor of neurosteroid synthesis, or 17PA [17-phenyl-(3,5)-androst-16-en-3-ol], a
blocker of neurosteroid effects onGABAA receptors.Moreover, the synaptic effects weremimicked by a combination of clonazepamwith
FGIN (2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide), a selective TSPO agonist, or a combination of clonazepam with
exogenous allopregnanolone. Consistent with these in vitro results, finasteride abolished the effects of midazolam on contextual fear
learningwhen administrated 1 d beforemidazolam injection. Thus, dual activation of CBRs andTSPO appears to result in unique actions
of clinically important BDZs. Furthermore, endogenous neurosteroids are shown to be important regulators of pyramidal neuron
function and synaptic plasticity.
Introduction
Benzodiazepines (BDZs) are widely used to treat anxiety, insom-
nia, and epilepsy, and also as intravenous anesthetics in which
sedation and amnesic effects are exploited for clinical benefit
(Olkkola and Ahonen, 2008). BDZs are known to depress CNS
activity via central BDZ receptors (CBRs) that are integral com-
ponents of certain GABAA receptors (GABAARs) (Rudolph and
Mo¨hler, 2004). BDZs also bind intracellular receptors on mito-
chondria that are distinct from CBRs and referred to as “periph-
eral BDZ receptors” (PBRs) based on expression at non-CNS loci
(Gavish et al., 1999). PBRs are nowknown as translocator protein
(18 kDa) (TSPO) (Papadopoulos and Lecanu, 2009), reflecting
their expression in the CNS and ability to bind other ligands
(James et al., 2006). TSPO activation promotes cholesterol traf-
ficking and synthesis of molecules derived from cholesterol, and
regulates multiple cellular processes including apoptosis (Hirsch
et al., 1998), immune function (Marino et al., 2001), and neuro-
steroid production (Costa et al., 1994). Neurosteroids, including
3-hydroxy-5-prenan-20-one [allopregnanolone (AlloP)], are
generated de novo in the CNS and are potent and effective mod-
ulators of GABAARs (Belelli and Lambert, 2005), possibly con-
tributing to clinical effects of certain psychotropic medications
(Kumar et al., 2009).
Recent studies indicate that TSPO agonists have anxiolytic
effects mediated by endogenous GABAergic neurosteroids
(Bitran et al., 2000; Da Settimo et al., 2008). Importantly, excita-
tory neurons appear to be the primary source of these neuros-
teroids (King et al., 2002; Agís-Balboa et al., 2006), raising the
possibility that neurosteroids are important local regulators
of pyramidal neuron function. We hypothesized that BDZ-
mediated neurosteroid production may modulate pyramidal
neuron firing and synaptic function. To test this, we compared
midazolam, an anesthetic BDZ used clinically for its amnesic
properties, and clonazepam, an anxiolytic and anticonvulsant
with relatively selective actions on CBRs (Mukhin et al., 1989;
Gavish et al., 1999). We compared effects on neurosteroid pro-
duction, network inhibition, and synaptic plasticity in the CA1
region of rat hippocampal slices, and, in vivo, on a form of
hippocampal-dependent learning. We found that midazolam,
but not clonazepam, enhances a specific form of network inhibi-
tion and inhibits long-term potentiation (LTP) and learning in a
neurosteroid-dependent fashion.
Materials andMethods
Animals. Protocols for animal use were approved by the Washington
University Animal Studies Committee in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
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Rats were maintained on a standard 12 h light/dark cycle with ad libitum
access to food.
Hippocampal slice preparation. Hippocampal slices were prepared
from postnatal day 30–32 male Sprague Dawley rats purchased from
Harlan (Zorumski et al., 1996). Rats were anesthetized with isoflurane
and decapitated. Slices were cut transversely into 500 m slices using a
rotary slicer in artificial CSF (ACSF) containing the following (in mM):
124 NaCl, 5 KCl, 2 MgSO4, 2CaCl2, 1.25 NaH2PO4, 22 NaHCO3, 10
glucose, bubbled with 95%O2/5%CO2 at 4–6°C. Acutely prepared slices
were placed on mesh in 10 ml beakers containing gassed ACSF and
maintained for at least 1 h at 30°C before experiments.
Immunohistochemistry. Hippocampal slices used for immunohisto-
chemistry were initially screened by electrophysiology. Using paired-
pulse stimulation delivered to the Schaffer collateral (SC) pathway at an
interval of 21 ms, we selected slices showing stable paired-pulse facilita-
tion of dendritic EPSPs and paired-pulse depression of population spikes
(PSs). Selection based on physiological screening markedly diminished
slice-to-slice variability in staining for 5-reduced neurosteroids and
was consistent with the criteria used for selecting slices used for electro-
physiological studies. Slices studied immunochemically were incubated
with various reagents in separate 10 ml beakers. After drug treatment,
slices were fixed in 4% paraformaldehyde in PBS for 30 min. Samples
were then washed with PBS and incubated in blocking solution (1%
donkey serum/PBS) for 2 h at 25°C. Slices were incubated with an anti-
body raised in sheep against 5-reduced neurosteroids diluted 1:2500 in
1% donkey serum/PBS and/or a commercial TSPO antibody diluted
1:500 in 1% donkey serum/PBS, for 48 h at 4°C. The polyclonal antibody
against 5-steroids has minimal cross-reactivity with other neuros-
teroids in rats (Bernardi et al., 1998).
After incubation with primary antibody, slices were rinsed with PBS
and incubated with secondary antibody for 2 h at 25°C. Alexa Fluor 488
donkey anti-sheep IgG (diluted 1:500) and Al-
exa Fluor 647 donkey anti-rabbit IgG (diluted
1:500)were used to visualize neurosteroids and
TSPO, respectively. After staining, slices were
washed with PBS and mounted onto micro-
scope slides with Fluoromount-G (Southern
Biotechnology Associates).
Confocal images were obtained using a 60
objective (1.4 numerical aperture), a C1 laser-
scanning confocal microscope and Z-C1 soft-
ware (Nikon Instruments) by a rater who was
unaware of the experimental condition. All pa-
rameters were kept constant within an experi-
ment. Digital images were analyzed and the
average intensity of the tissue was measured
using MetaMorph software (Universal Imag-
ing). Data were collected from at least three
independent samples.
Electrophysiology. At the time of study, slices
were transferred individually to a submerged
recording chamber. Experiments were per-
formed at 30°C with continuous bath perfu-
sion of ACSF at 2 ml/min. Extracellular
recordings were obtained from the apical den-
dritic layer of the CA1 region for analysis of pop-
ulation EPSPs and from the cell body layer for
analysis of PSs. EPSPs were measured by their
maximal slopes, and PSs were measured as a
maximal height from the apex of the first positive
peak to the most negative point of the spike.
To study proximal inhibition, we used a
paired-pulse paradigm in which stimulation
adjacent to the pyramidal cell layer was paired
15 ms later with orthodromic stimulation in
stratum radiatum. Previous studies indicated
that these proximal inhibitory inputs differ in
their time course and pharmacology compared
with distal dendritic or recurrent inhibitory in-
puts (Pearce, 1993;Weiner et al., 1997; Izumi et
al., 2007). For these studies, orthodromic stimuli were applied at an
intensity that activated 90–100%maximal PSs and the proximal stimuli
were administered at an intensity that diminished baseline orthodromic
PSs by 30–70%. The effects of BDZ modulators, AlloP and finasteride,
were determined by changes in the degree of orthodromic-evoked spike
depression after proximal stimulation.
For LTP studies, evoked EPSPs were elicited with 0.1 ms constant
current pulses through a bipolar stimulating electrode (Rhodes Medical
Instruments) placed in the Schaffer collateral/commissural (stratum ra-
diatum) pathway. EPSPs were monitored by applying single stimuli to
the Schaffer collaterals every 60 s at an intensity sufficient to elicit half-
maximal responses. After establishing a stable baseline for at least 10min
and a control input–output curve, LTP was induced by applying a single
100 Hz 1 s high-frequency stimulation (HFS) using the same intensity
stimulus. Input–output curves were repeated 60 min after HFS. For
recording NMDA receptor-mediated synaptic responses (NMDA-
EPSPs), ACSF containing low Mg2 (0.1 mM) and high Ca2 (2.5 mM)
was used to facilitate activation ofNMDA receptor-gated channels. Non-
NMDA receptor-mediated components of synaptic response were
blocked by CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (30 M).
Signals were digitized and analyzed using the pCLAMP software (Molec-
ular Devices).
Behavioral studies. Behavioral tests were conducted by an experi-
menter who was unaware of treatment condition. The testing apparatus
consisted of two chambers equipped with a floor made of stainless-steel
rods (4 mm diameter, spaced 10 mm apart). The grid floor in the dark
compartment (12 20 16 cm)was connected to an electrical source so
that a shock could be delivered when a rat entered the compartment. The
adjoining safe compartment (30  20  16 cm) was illuminated with
four 13W lights. Light intensity in the center of the illuminated chamber
Figure 1. Localization of 5-reduced neurosteroids (AlloP) and TSPO in the CA1 region of rat hippocampal slices. A, Moderate
AlloP staining was observed in cell bodies of pyramidal neurons in a naive slice 2 h after dissection. This staining was markedly
attenuated by 45 min incubation with 1 M finasteride (B) and augmented by 30 min administration of 0.1 M MDZ (C).
Enhancement byMDZwas diminished by finasteride pretreatment (D). All slices are from the same hippocampus. Double staining
against AlloP (green) and TSPO (red) in a naive slice shows colocalization in pyramidal neurons (E).F, Summary of immunostaining
studies shown in A–D. Fluorescence intensity (arbitrary units) in the cell body layer was augmented by MDZ and attenuated by
finasteride.G, Summary of immunostaining studies comparingMDZ, clonazepam, and FGIN. Unlike 0.1MMDZ and 1M FGIN, 5
M clonazepam had no effect on AlloP immunostaining. Data are mean SEM. *p 0.01 by Holm–Sidak post hoc test.
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was 1000 lux, and that in the dark chamber was
10 lux. On the initial day of training, rats
were placed in the apparatus without turning
on the light and allowed to habituate for 10min
in each compartment. Finasteride (50 mg/kg
suspended in Liposyn III, 30%) or Liposyn III
alone was administered by intraperitoneal in-
jection on the same day. On the next day, each
animal was placed in the illuminated compart-
ment, and we confirmed that the rat promptly
entered the dark compartment. No footshocks
were given during the preexposure period. An-
other dose of finasteride or Liposyn III was
injected 40min beforemidazolam (MDZ) injec-
tion.MDZ(3mg/kg,dissolved in salinewith son-
ication) or salinewas injected 20minbefore trials
in which a footshock was administered when the
rat entered thedark chamber.All ratswereplaced
in the illuminated compartment and allowed to
enter the dark compartment spontaneously.
When rats escaped from the dark compartment,
they were returned to their original home cages.
On the third day, all rats were again placed in the
illuminated chamber for amaximumdurationof
3min andmonitored for the time elapsed before
entering the dark compartment.
Statistical analysis. All data are expressed as
mean  SEM. In studies using hippocampal
slices, “n” represents the number of slices studied
in a given condition, and, unless statedotherwise,
data were normalized with respect to initial con-
trol responses. Points in the graphswithout error
bars have an error range smaller than the symbol
size. Student’s t test was used for comparisons
between two groups. If a test of equal variance
failed, the nonparametric Mann–Whitney rank
sum test was applied. For multiple comparisons,
ANOVA followed by post hoc Holm–Sidak test
was used. Statistical analyses were performed us-
ing commercial software (SigmaStat 3.11; Systat
Software). Values of p  0.05 were considered
statistically significant.
Statistical comparisons in studies of LTP are
based on analysis of input–output curves at
baseline and 60 min after HFS, representing the degree of change at the
half-maximal point on the input–output curves compared with baseline
responses.
Materials. 2-[2-(4-Fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacet-
amide [FGIN-1-27 (FGIN)], flumazenil, and -cyclodextrin were pur-
chased fromTocris. Finasteride andAlloPwere obtained fromSteraloids.
ADVASEP-7 (-cyclodextrin sulfobutyl ether) was obtained from CyDex.
All other chemicals were purchased from Sigma-Aldrich. Anti-allopregna-
nolone antiserumwas purchased fromDr. Robert Purdy (University of Cal-
ifornia, SanDiego,La Jolla,CA).TSPOantibodyandTSPOblockingpeptide
were purchased from BioVision. Alexa Fluor 488 and Alexa Fluor 647 were
purchased from Invitrogen. Liposyn III was purchased fromHospira.
Results
AlloP and TSPO in the hippocampus
We initially examined the expression of GABAergic neuros-
teroids in the CA1 hippocampal region using a previously char-
acterized antibody that recognizes AlloP and other 5-reduced
steroids (Bernardi et al., 1998; Saalmann et al., 2007). In pilot
studies, we found that the intensity and distribution of neuroste-
roid staining correlatedwith baseline physiological responses. Slices
exhibiting stable paired-pulse facilitation of dendritic EPSPs
and paired-pulse depression of PSs, physiological signatures of
slice health, showed consistent low-level slice-to-slice baseline
neurosteroid staining. Thus, slices used for subsequent experi-
ments were initially screened electrophysiologically. In naive
slices, cell bodies of CA1 pyramidal neurons were diffusely posi-
tive for 5-reduced steroids (Fig. 1A), consistent with previous
studies indicating that principal neurons are the major source of
GABAergic neurosteroids (Agís-Balboa et al., 2006; Saalmann et
al., 2007). Coincubations with exogenous AlloPmarkedly dimin-
ished this staining, confirming antibody specificity (supplemen-
tal Fig. S1C, available at www.jneurosci.org as supplemental
material). Similarly, pretreatment of slices with 1 M finasteride,
a 5 reductase inhibitor that blocks AlloP synthesis (Finn et al.,
2006), mostly eliminated staining (Fig. 1B,F) as did injection of
finasteride (50 mg/kg, i.p.) administered 1 d before dissection
(supplemental Fig. S1D, available at www.jneurosci.org as sup-
plemental material). These latter results suggest that 5-reduced
steroids are synthesized constitutively in the hippocampus.
When naive slices were treatedwith 0.1MMDZ for 30min, CA1
pyramidal neurons showed augmented staining (Fig. 1C), indi-
cating that this anesthetic BDZ enhances neurosteroid produc-
tion. The enhanced staining by MDZ was inhibited by
pretreatment with finasteride (Fig. 1D,F). In contrast, 5 M
clonazepam, a selective CBR agonist (Lo¨scher et al., 1996), did
not alter steroid staining, whereas immunostaining was en-
Figure 2. Effects of MDZ on proximal inhibition. PSs were evoked by Schaffer collateral stimulation at an intensity that gave a
maximal response. The gray symbols and thin black traces to the right of the graphs represent PSs without preceding proximal
stimulation. Conditioning stimulation with a second electrode positioned adjacent to the pyramidal cell layer (green symbols and
green traces) depressed PSs by50% in both panels. PS amplitudes were measured from the initial positive peak to the nadir of
the spike as shown in the inset toA.A, Proximal inhibitionwas slowly augmented by 0.1MMDZ (black bar) andwas overcomeby
1MPTX (hatchedbar). The redandblue circles correlatewith rawtraces shown to the right of thegraph.B, Finasteride (whitebar)
overcame proximal inhibition and prevented enhancement by MDZ (black bar). The traces show examples of raw PSs elicited by
Schaffer collateral stimulation after conditioning proximal stimulation at the times indicated to the right of the raw traces. To
facilitate comparisons, the previous raw trace is shown as a thin solid line in the color that reflects the time itwas obtained (e.g., at
90 inA, the 45 trace is shown in a thin red line, whereas the actual 90 trace is shown in blue, the same color as the symbol in the
graph). Error bars indicate SEM.
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hanced by FGIN, a selective TSPO agonist (Romeo et al., 1992)
(Fig. 1G; supplemental Fig. S1A, available at www.jneurosci.org
as supplemental material).
Antibodies against TSPO revealed similar pyramidal neuron ex-
pression in the CA1 region, and double staining with the neuro-
steroid antibody showed colocalization in pyramidal neurons
(Fig. 1E; supplemental Fig. S1B, available at www.jneurosci.org
as supplemental material). TSPO immunoreactivity was inhib-
ited completely by coincubation with TSPO blocking peptide,
confirming antibody specificity (supplemental Fig. S1E, available at
www.jneurosci.org as supplemental material). Unlike neurosteroid
staining,TSPOimmunoreactivitywasnotalteredacutelyby1MMDZ
(supplementalFig.S1B,availableatwww.jneurosci.orgassupplemental
material). Together, these results indicate that 5-reduced neuros-
teroids are synthesized in CA1 pyramidal neurons via TSPO and
that some, but not all, BDZs enhance their production.
Effects of BDZs on proximal inhibition
BecauseMDZ enhances neurosteroid staining in cell bodies and
proximal processes of pyramidal neurons, we hypothesized that
MDZ would modulate CA1 spike firing, particularly when ad-
ministered with stimulation that activates inhibition at or near
the cell body layer.We tested this by stim-
ulating proximal inputs to pyramidal neu-
ronsbefore triggeringPS firingviaSCinputs
(Pearce, 1993; Weiner et al., 1997; Izumi et
al., 2007). SC stimulation was adjusted to
evoke a maximal PS while proximal stimu-
lationwas delivered at an intensity that pro-
duced 50% depression of PS amplitude
when administered 15 ms before the SC
stimulus. At 0.1M,MDZ slowly butmark-
edly enhanced proximal inhibition (paired-
pulse PS height in control: 58.4 10.5% of
baseline vs 9.3 6.0% inMDZ; n 5; p
0.01 by paired t test) (Fig. 2A). The en-
hanced inhibition was reversed by 1 M pi-
crotoxin (PTX), indicating involvement of
GABAARs (66.7 17.8%baseline; p 0.05
vsMDZ alone) (Fig. 2A).
To determine whether neurosteroids
contribute to these effects, we adminis-
tered finasteride before MDZ. At 1 M,
finasteride alone slowly attenuated proxi-
mal inhibition (46.0  16.0% of baseline
in control vs 94.0 30.5% in finasteride;
n 5; p 0.05) (Fig. 2B). In the presence
of finasteride, MDZ failed to alter PS fir-
ing (94.1  28.9% of baseline) (Fig. 2B).
Consistent with the effects of finasteride,
we also found that 17-phenyl-(3,5)-
androst-16-en-3-ol (17PA), a synthetic
steroid that inhibits the effects of 5-
reduced neurosteroids on GABAARs
(Mennerick et al., 2004), attenuated prox-
imal inhibition of PS firing (supplemental
Fig. S2A, available at www.jneurosci.org
as supplemental material). These results
strongly suggest that neurosteroids are in-
volved in both the depression of PS firing
resulting from proximal stimulation and
MDZ-mediated enhancement of proxi-
mal inhibition.
Because neurosteroid synthesis involves TSPO, we examined
the effects of FGIN on proximal inhibition. At 1 M, FGIN alone
failed to enhance proximal inhibition (53.7 8.8% of baseline in
control vs 52.7 9.3% in FGIN; n 5) (Fig. 3A), suggesting that,
although neurosteroids are involved in this form of spike depres-
sion, activation of TSPO alone is insufficient to enhance the de-
pression. This raises the possibility that combined effects on both
TSPO and CBRs are required to produce the enhancement by
MDZ. Indeed, coadministration of FGIN with 5 M clonazepam
augmented proximal depression (69.9 8.8%of baseline in con-
trol vs 19.5  8.7% in FGIN plus clonazepam; n  5; p  0.05)
(Fig. 3C), even though clonazepam alone did not alter PS inhibi-
tion (50.8  18.8% of baseline in control vs 56.3  1.3% in
clonazepam; n 5) (Fig. 3B). Clonazepam also enhanced prox-
imal inhibition in the presence of 0.1 M exogenous AlloP (con-
trol, 57.8 9.9%, vs AlloP, 19.4 7.1%; n 5; p 0.01) (Fig.
3D), a steroid concentration that does not alter PS inhibition
alone (59.0  14.1%) (Fig. 3D). These results indicate that the
effects of MDZ on proximal inhibition require dual activation of
CBRs and TSPO. Consistent with this, flumazenil, a selective
CBR antagonist, blocked the effects of MDZ but, unlike finas-
teride and 17PA, did not alter proximal inhibition when admin-
Figure 3. Effects of clonazepam on proximal inhibition. A, At 1M, FGIN (hatched bar) had no effect on proximal inhibition.B,
Similarly at 5M, clonazepam alone had no effect on proximal inhibition. C, A combination of 1M FGIN (hatched bar) and 5M
clonazepam (black bar) enhanced proximal inhibition. D, Although 0.1 M AlloP (cross hatched bar) had no effect on spike
inhibition, a combination of AlloP and 5M clonazepam (black bar) augmented proximal inhibition. Raw traces above the graphs
show PSs elicited by Schaffer collateral stimulation after conditioning proximal stimulation at the times indicated using the same
coding as in Figure 2. Error bars indicate SEM.
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istered alone (supplemental Fig. S2B,
available at www.jneurosci.org as supple-
mental material).
Effects of MDZ and neurosteroids
on LTP
Because spike firing is required for synap-
tic plasticity (Phillips et al., 2008), we ex-
amined the effects of MDZ on LTP
induction. Administration of MDZ for 30
min before a single 100 Hz  1 s HFS
blocked LTP in a concentration-dependent
manner (EPSP change: 151.7  4.1% of
baseline in naive controls, 149.3 5.5% of
baseline at 0.01Mvs 102.4 1.3%of base-
line at 0.1 M, measured 60 min after HFS;
n 5 each) (Fig. 4A). This LTP inhibition
was overcome by 1 M PTX (EPSP change:
133.5 3.6% of baseline; n 5; p 0.001
vs0.1MMDZalone) (Fig.4B)andby1M
flumazenil (EPSP change: 142.4 6.9% of
baseline; n 5; p 0.008 vs 0.1 M MDZ
alone) (Fig. 4B), indicating a role for
GABAARs andCBRs. A 50-fold higher con-
centration of clonazepam (5M), however,
hadnoeffectonLTP(EPSPchange:174.6
10.7%of baseline) (Fig. 4C), suggesting that
CBRs alone are insufficient to alter synaptic
plasticity. At concentrations5M, clon-
azepam significantly depressed baseline
synaptic transmission, but even at 20 M
did not completely block LTP induction
(supplemental Fig. S3C, available at www.
jneurosci.org as supplemental material).
FGIN alone also failed to inhibit LTP
(EPSP change: 157.2  8.8% of baseline;
n 5) (Fig. 4C), although combination of
clonazepam and FGIN diminished LTP
(EPSP change: 113.4  7.9% of baseline;
n  5; p  0.001 vs clonazepam alone)
(Fig. 4C). Thus, similar to proximal inhi-
bition of spike firing, LTP inhibition
requires both CBRs and TSPO. Also con-
sistent with this, 1 M finasteride over-
came the effects of MDZ on LTP (EPSP
change: 155.0 13.0% of baseline; n 5;
p  0.008 vs 0.1 M MDZ alone) (Fig.
4D), as did a neurosteroid antagonist
(17PA) (supplemental Fig. S3A, available
at www.jneurosci.org as supplemental material), removal of en-
dogenous neurosteroids with cyclodextrins (supplemental Fig.
S3B, available at www.jneurosci.org as supplemental material),
and a TSPO antagonist (supplemental Fig. S4B, available at www.
jneurosci.org as supplemental material) (Shu et al., 2007). Further-
more, a combination of clonazepam and FGIN failed to inhibit LTP
in the presence of finasteride (EPSP change: 152.6 9.9% of base-
line; n  5; p  0.008 vs 0.1 M MDZ alone) (Fig. 4C), although
clonazepam was effective when administered in the presence of 0.1
MAlloP (supplemental Fig. S3D, available at www.jneurosci.org as
supplemental material).
We also examined the time course of effects on LTP. At 0.1
M,MDZ inhibited LTPwhen administered for 30min (Fig. 4A)
but not 10 min before HFS (EPSP change: 153.1  10.6% of
baseline; n  5) (Fig. 5A). We subsequently examined whether
exogenous AlloP augments the inhibitory effects of 0.01 M
MDZ.Although 0.01MMDZadministered alone for 30min did
not alter LTP (Fig. 4A), 0.01 M MDZ administered for 10 min
before HFS in the presence of 0.1 M AlloP blocked LTP induc-
tion (EPSP change: 106.1  3.3% of baseline; n  5) (Fig. 5A).
These observations indicate that brief exposures to low concen-
trations of MDZ are effective under conditions in which neuros-
teroids levels are increased, and that longer exposures to higher
concentrations of MDZ are sufficient to promote neurosteroid
synthesis and impair synaptic plasticity on their own. Adminis-
tration of 0.1 M AlloP alone did not modulate LTP induction
(EPSP change: 148.3  2.7% of baseline; n  5; p  0.514 vs
control LTP). Furthermore, AlloP did not alter NMDA receptor-
Figure 4. Effects of neurosteroidmodulators on LTP. A, In control slices, LTP is readily induced (green triangles) by a single 100
Hz1 sHFS (arrow). Thirtyminute administrationof 0.01MMDZ (thin black bar) failed to alter LTP (white squares),whereas 0.1
MMDZ (thick black bar) blocked LTP induction (white circles). B, In the presence of 1M PTX (purple hatched bar), 0.1MMDZ
did not inhibit LTP (purple squares); PTX alone had no effect on LTP at this concentration. Administration of 1M flumazenil (red
bar) overcame the inhibitory effect ofMDZ (red circles). C, Although 5M clonazepam (black bar, white circles) or 1M FGIN alone
(blue bar, blue squares) did not alter LTP, a combination of these agents inhibited LTP (blue triangles). Finasteride (purple bar)
overcame the effects of clonazepam plus FGIN (purple triangles). D, Effects of 0.1M MDZ (black bar) on LTP were overcome by
finasteride (purple bar, purple diamonds). The traces depict EPSPs before (thin black lines) and60min afterHFS (trace colorsmatch
symbols colors in the graphs). In all graphs, a 100 Hz 1 s HFS was administered at time 0 (arrows). Error bars indicate SEM.
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mediated synaptic responses (NMDA-EPSP change: 104.2 4.0%
of baseline; n 5; p 0.403 by paired t test).
Effects of neurosteroids in vivo
MDZ also failed to inhibit LTP in slices from rats treated with
finasteride (50 mg/kg, i.p.) 1 d before dissection (EPSP change:
158.7 6.9% of baseline; n 5; p 0.008 vs 0.1MMDZ alone)
(Fig. 5B). Similarly, we found that in vivo finasteride pretreat-
ment abolished the effects of MDZ on
contextual fear learning. Control rats
readily associated entry into a dark cham-
ber with administration of a footshock,
and avoided the dark compartment when
retested 24 h later. At a dose that produced
little behavioral sedation (3mg/kg, i.p., 20
min before conditioning),MDZ inhibited
this learning. In contrast, rats treated with
clonazepam (3 mg/kg, i.p.) showed mild
behavioral sedation and fear conditioning
that did not differ from controls (Fig. 6).
Consistent with the LTP results, rats pre-
treated with finasteride 1 d before MDZ
and conditioning had no difficulty in
learning the association (Fig. 6).
Discussion
Excitatory neurons appear to play amajor
role in brain neurosteroid synthesis. In the
hippocampus, pyramidal neurons are im-
munopositive for 5-reduced steroids
(Saalmann et al., 2007) and are the pri-
mary, if not exclusive, cells that express
5-reductase (Agís-Balboa et al., 2006), a
key synthetic enzyme, and StAR (steroi-
dogenic acute regulatory protein), a mo-
lecular shuttle that delivers cholesterol to mitochondria for
steroid synthesis (Wehrenberg et al., 2001). We found that 5-
steroids are present constitutively in cell bodies and proximal
processes of pyramidal neurons and colocalize with TSPO, a mi-
tochondrial transporter activated by some, but not all BDZs. Al-
though a specific TSPO agonist (FGIN) enhances steroid
immunoreactivity, indicating that TSPO activation is sufficient
to drive neurosteroid production, only certain BDZs promote
steroid synthesis. Because previous reports indicated that TSPO
is expressed in glia (Falchi et al., 2007), it is possible that steroid
precursors derive from glia. However, colocalization of TSPO
with 5-reduced steroids suggests that hippocampal neuroste-
roid synthesis can be principal neuron specific.
The expression of 5-reduced steroids in excitatory neurons
suggests that these neurosteroids may be key modulators of py-
ramidal neuron function.Wepreviously reported that finasteride
overcomes inhibition of PS firing resulting from proximal stim-
ulation and prevents enhancement of this inhibition by ethanol
(Izumi et al., 2007). These results suggest that neurosteroids play
a paracrine or perhaps autocrine role in modulating spike firing.
In the present study, we found that both finasteride and an an-
tagonist of 5-reduced neurosteroid actions on GABAARs re-
verse proximal inhibition in naive slices. Neither agent alone
modulates GABAARs, strongly suggesting that neurosteroids are
key endogenous mediators of, or, at the minimum, important
cofactors in this form of spike inhibition. It also appears that
ambient levels of neurosteroids in pyramidal neurons may help
to determine basal firing properties. Neurosteroids, however,
seem to play a permissive role inmodulating proximal inhibition
because simply increasing steroid levels above baseline (e.g., with
FGIN or MDZ in the presence of flumazenil) is insufficient to
increase proximal inhibition further. Additional experiments are
required to test these hypotheses. Nonetheless, the block of the
effects of MDZ by either finasteride or a CBR antagonist, and the
failure of FGIN alone to augment proximal inhibition, indicate
that activation of both CBRs and TSPO is necessary for BDZs to
Figure5. Time-dependent effects ofMDZandpreventionby in vivo finasteride.A, A 10minadministrationof 0.1MMDZalone
(thick black bar) failed to alter LTP (white circles), although 0.01MMDZ (thin black bar) administered for 10min in the presence
of AlloP (gray bar) inhibited LTP (gray circles).B, MDZ (black bar) failed to inhibit LTP in slices from rats pretreatedwith finasteride
in vivo (50 mg/kg, i.p., 1 d before dissection; white triangles). Traces depict EPSPs before (thin black lines) and 60 min after HFS
(trace colorsmatch symbols colors in thegraphs). In all graphs, the100Hz1 sHFSwasadministeredat time0 (arrows). Error bars
indicate SEM.
Figure 6. Neurosteroids contribute to amnesic effects ofMDZ. The graph shows the average
time that rats spent in the lit compartment of a two-compartment chamber 1 d after receiving
a footshock in the dark compartment. Twenty-four hours after conditioning, control rats rarely
entered the dark compartment during a 180 s observation period (n 5), whereas rats treated
with MDZ (3mg/kg, i.p.) 20min before the conditioning shock readily reentered and preferred
the dark chamberwhen tested 24 h later (n 6). At the dose used,MDZ did not alter either the
time to enter the dark compartment [4.72.2 s (MDZ) vs 8.83.9 s] or the time to escape the
dark compartment after shock [3.2 0.9 s (MDZ) vs 3.1 0.8 s]. Similar to controls, rats
pretreated with finasteride (50mg/kg) before MDZ treatment were reluctant to enter the dark
compartment (n5). For these studies, finasteridewasadministered twicewithan initial dose
24 h before conditioning and a second dose before treatment with MDZ on the day of condi-
tioning. Rats treated with clonazepam (3mg/kg, i.p.) before conditioning did not differ signif-
icantly from controls (n 6). ##p 0.01 by Mann–Whitney test versus control; (##)p 0.01
by Mann–Whitney test versus MDZ alone. Error bars indicate SEM.
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modulate spike inhibition. Although clonazepam alone failed to
augment proximal inhibition, clonazepam plus FGIN mimicked
MDZ, supporting the idea that both types of BDZ receptors are
important. How neurosteroids and CBRs interact is not certain
but could involve changes in GABAAR affinity or effects on
GABA-gated channels. Additionally, the involvement of neuros-
teroids in the effects of MDZ raise the possibility that GABAARs
lacking the 2-subunits required for CBR actions participate in
modulating proximal inhibition and LTP. In particular, extra-
synaptic receptors expressing 4 or  subunits receptors are in-
sensitive to CBR agonists and could participate in the effects of
neurosteroids. CBR agonist insensitivity would also be observed
withxxGABAARswhilemaintaining neurosteroidmodulation
(Rudolph and Mo¨hler, 2004; Belelli and Lambert, 2005).
Although LTP is driven by and expressed at glutamate syn-
apses, pyramidal neuron spiking is an important factor in LTP
induction (Phillips et al., 2008). Thus, it appears that the effects of
MDZ on proximal inhibition and LTP induction are related.
Given the proposed role of LTP as a memory mechanism (Bliss
and Collingridge, 1993; Martin et al., 2000), the factors contrib-
uting to LTP inhibition may also strongly contribute to MDZ-
induced amnesia, as observed in our behavioral studies. Local
injection of MDZ in the hippocampus adversely affects memory
acquisition, suggesting that amnesic effects involve the hip-
pocampus (Barros et al., 1998). A recent study reported that
AlloP facilitates NMDA-EPSPs and LTP in postpubertal female
mice but inhibited LTP in prepubertalmice (Shen et al., 2010). In
the present study, AlloP alone did not affect eitherNMDA-EPSPs
or LTP induced by high-frequency stimulation in slices from
prepubertal 30-d-old male rats. Differences in sex, pubertal sta-
tus, and stimulation paradigms (theta burst stimulation vs 100
Hz  1 s tetanus) likely account for differences between these
studies.
BDZs are known to disrupt human memory (Dundee and
Wilson, 1980; Buffett-Jerrott and Stewart, 2002). When used to
treat anxiety or insomnia, this can result in anterograde amnesia,
akin to alcohol-induced “blackouts” (White, 2003). When used
in anesthesia, however, memory impairment helps to prevent
intraoperative awareness, a condition that can result in recollec-
tion of painful events during medical or surgical procedures
(Samuelsson et al., 2007). Our results indicate that effects of
BDZs on LTP require both CBRs and TSPO (supplemental Fig.
S5, available at www.jneurosci.org as supplemental material);
thus, only certain BDZs are likely to produce anterograde amne-
sia when administered alone. Clonazepam alone had no effect on
either proximal inhibition or LTP. Importantly, however, when
clonazepam was administered under conditions in which neuro-
steroid levels were acutely elevated, it had adverse effects on LTP
and would be expected to have prominent effects on memory
formation (supplemental Fig. S5, available at www.jneurosci.org
as supplemental material). Increases in neurosteroid levels could
occur during acute psychosocial stress or in the presence of other
drugs such as ethanol or psychotropic medications that enhance
neurosteroid production (Barbaccia, 2004; Sanna et al., 2004;
Ugale et al., 2004; Verleye et al., 2005). Importantly, our results
suggest that selective CBR agonists are not the sole culprits in
anterograde amnesia, but rather produce deleterious effectswhen
working in concert with elevated levels of neurosteroids. Simi-
larly, selective TSPO agonists are unlikely to cause memory im-
pairment alone, but will have adverse actions in the presence of
mechanistically different modulators of GABAARs or perhaps
modulators of other receptors (e.g., NMDA receptors in the case
of ethanol).
Our results have implications for the design of novel neuropsy-
chiatric medications and for augmenting or minimizing effects as-
sociated with current clinically used medications. Based on the
effects of clonazepam, activation of CBRs alone appears to be suffi-
cient to produce anticonvulsive and anxiolytic actions. Specific li-
gands for TSPO may share some of these effects (Rupprecht et al.,
2009), whereas agents that activate both CBRs and TSPO are also
expected to have amnesic and anesthetic properties. This also sug-
gests that clinical conditions or treatments that alter neurosteroid
levels can significantly modulate the effects of agents with more se-
lective actions at other receptors, leading to novel therapeutic and
adverse actions.
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